NEW YORK (GenomeWeb) – A recently published study by researchers from New Zealand-based diagnostic firm Pacific Edge and collaborators has shown that the firm's molecular diagnostic test for bladder cancer recurrence, Cxbladder Monitor, outperforms cytoscopy and other commonly used US Food and Drug Administration-approved urine-based tests for bladder cancer monitoring.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.